BioSpace News Archive

The U.S. Space Force’s Space Launch Delta 30 at Vandenberg Space Force Base has awarded Amentum a $59 million contract

C4X entered into a licensing deal with AstraZeneca to develop an oral treatment for COPD and other inflammatory and respiratory illnesses that could reach $402 million.

Spectrum Pharmaceuticals made the call Friday to slash three-fourths of its workforce on the heels of a Complete Response Letter from the FDA.

Amentum has been recognized as a Top 25 Veteran Employer for 2022 by the Veteran Employment Project, the jobs arm of Military.com

C4X Discovery Holdings plc, a pioneering Drug Discovery company, has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402 million1, for its NRF2 Activator programme.

GenFleet Therapeutics today announced the preliminary safety and efficacy data from the Phase I study of GFH009 monotherapy for treatment of relapsed/refractory hematological malignancies will be shared at the 2002 Annual Meeting of the American Society of Hematology (ASH) in New Orleans, Louisiana, on December 12, 2022.

Oxitope is pleased to announce the appointment of Professor Gregg Stone as a clinical key opinion leader for its lead antibody programme targeting myocardial infarction induced reperfusion injury.

Immuneering Corporation today announced that the first patient commenced treatment on November 21 in its Phase 1/2a (NCT05585320) clinical trial of lead asset, IMM-1-104. IMM-1-104 is designed to provide pan-RAS activity through deep cyclic inhibition of the MAPK pathway with once-daily dosing.

Viridian Therapeutics, Inc. today announced that senior management will participate in the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022.

Replay, a genome writing company reprogramming biology by writing and delivering big DNA, today announced that it has received a $1.56 million grant from the Bill & Melinda Gates Foundation to accelerate the development of uCell™, a proprietary hypoimmunogenic technology platform.